Cover Image

Therapeutic potential of cannabinoids in psychosis

Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly fulfills a homeostatic role in terms of neurotransmission but also with res...

Full description

Saved in:
Bibliographic Details
Main Author: Leweke, F. Markus (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: Biological psychiatry
Year: 2015, Volume: 79, Issue: 7, Pages: 604-612
ISSN:1873-2402
DOI:10.1016/j.biopsych.2015.11.018
Online Access:Verlag, Volltext: https://doi.org/10.1016/j.biopsych.2015.11.018
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0006322315009956
Get full text
Author Notes:F. Markus Leweke, Juliane K. Mueller, Bettina Lange, and Cathrin Rohleder

MARC

LEADER 00000caa a2200000 c 4500
001 1663143072
003 DE-627
005 20220816133523.0
007 cr uuu---uuuuu
008 190411r20162015xx |||||o 00| ||eng c
024 7 |a 10.1016/j.biopsych.2015.11.018  |2 doi 
035 |a (DE-627)1663143072 
035 |a (DE-599)KXP1663143072 
035 |a (OCoLC)1341209552 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Leweke, F. Markus  |e VerfasserIn  |0 (DE-588)1052094287  |0 (DE-627)787796859  |0 (DE-576)407845941  |4 aut 
245 1 0 |a Therapeutic potential of cannabinoids in psychosis  |c F. Markus Leweke, Juliane K. Mueller, Bettina Lange, and Cathrin Rohleder 
264 1 |c 2016 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Available online 28 November 2015 
500 |a Gesehen am 11.04.2019 
520 |a Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly fulfills a homeostatic role in terms of neurotransmission but also with respect to inflammatory processes. Two main approaches to the modulation of endocannabinoid functioning have been chosen so far. First, the selective blockade or inverse agonism of the type 1 cannabinoid receptor has been tested for the improvement of acute psychotic symptoms, as well as for the improvement of cognitive functions in schizophrenia. This was not effective in either case. Second, the modulation of endocannabinoid levels by use of the phytocannabinoid cannabidiol and selective fatty acid amide hydrolase inhibitors has been proposed, and the antipsychotic properties of cannabidiol are currently being investigated in humans. Unfortunately, for most of these trials that have focused on psychopathological and cognitive effects of cannabidiol, no published data are available. However, there is first evidence that cannabidiol may ameliorate psychotic symptoms with a superior side-effect profile compared with established antipsychotics. In conclusion, several clinical trials targeting the ECS in acute schizophrenia have either been completed or are underway. Although publicly available results are currently limited, preliminary data indicate that selected compounds modulating the ECS may be effective in acute schizophrenia. Nevertheless, so far, sample sizes of patients investigated are not sufficient to come to a final judgment, and no maintenance studies are available to ensure long-term efficacy and safety. 
534 |c 2015 
650 4 |a Antipsychotic 
650 4 |a Cannabidiol 
650 4 |a Cannabinoid receptors 
650 4 |a Clinical trial 
650 4 |a Endocannabinoids 
650 4 |a Schizophrenia 
773 0 8 |i Enthalten in  |t Biological psychiatry  |d Amsterdam [u.a.] : Elsevier Science, 1985  |g 79(2016), 7, Seite 604-612  |h Online-Ressource  |w (DE-627)306654296  |w (DE-600)1499907-9  |w (DE-576)115780807  |x 1873-2402  |7 nnas  |a Therapeutic potential of cannabinoids in psychosis 
773 1 8 |g volume:79  |g year:2016  |g number:7  |g pages:604-612  |g extent:9  |a Therapeutic potential of cannabinoids in psychosis 
856 4 0 |u https://doi.org/10.1016/j.biopsych.2015.11.018  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0006322315009956  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190411 
993 |a Article 
994 |a 2016 
998 |g 1052094287  |a Leweke, F. Markus  |m 1052094287:Leweke, F. Markus  |d 60000  |e 60000PL1052094287  |k 0/60000/  |p 1  |x j 
999 |a KXP-PPN1663143072  |e 3421448914 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Therapeutic potential of cannabinoids in psychosis","title":"Therapeutic potential of cannabinoids in psychosis"}],"name":{"displayForm":["F. Markus Leweke, Juliane K. Mueller, Bettina Lange, and Cathrin Rohleder"]},"origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"id":{"eki":["1663143072"],"doi":["10.1016/j.biopsych.2015.11.018"]},"relHost":[{"note":["Gesehen am 08.01.20","Ungezählte Beil.: Supplement"],"language":["eng"],"recId":"306654296","physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1985-","dateIssuedKey":"1985","publisher":"Elsevier Science","publisherPlace":"Amsterdam [u.a.]"}],"part":{"extent":"9","year":"2016","pages":"604-612","volume":"79","issue":"7","text":"79(2016), 7, Seite 604-612"},"id":{"issn":["1873-2402"],"eki":["306654296"],"zdb":["1499907-9"]},"title":[{"subtitle":"a journal of psychiatric neuroscience ; a publication of the Society of Biological Psychiatry","title":"Biological psychiatry","title_sort":"Biological psychiatry"}],"disp":"Therapeutic potential of cannabinoids in psychosisBiological psychiatry","pubHistory":["Nachgewiesen 20.1985 -"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"recId":"1663143072","language":["eng"],"physDesc":[{"extent":"9 S."}],"person":[{"given":"F. Markus","family":"Leweke","display":"Leweke, F. Markus","role":"aut","roleDisplay":"VerfasserIn"}],"note":["Available online 28 November 2015","Gesehen am 11.04.2019"]} 
SRT |a LEWEKEFMARTHERAPEUTI2016 

Similar Items